Novartis Drug Patent Portfolio
Novartis owns 54 orange book drugs protected by 297 US patents with Alomide having the least patent protection, holding only 1 patent. And Promacta with maximum patent protection, holding 28 patents. Given below is the list of Novartis's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12208102 | Methods of treating cancer | 18 Sep, 2041 | Active |
| US11951101 | Methods of using factor B inhibitors | 15 Jul, 2041 | Active |
| US11603363 | Crystalline form of LNP023 | 25 May, 2041 | Active |
| US11491137 | Methods of improving renal function | 16 Dec, 2040 | Active |
| US11998526 | Methods of improving renal function | 16 Dec, 2040 | Active |
| US12121509 | Methods of improving renal function | 16 Dec, 2040 | Active |
| US12252479 | Crystalline forms OF N-[4-(chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide | 17 May, 2040 | Active |
| US11407735 | Crystalline forms of N-[4-(Chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide | 14 May, 2040 | Active |
| US12252478 | Crystalline forms of N-[4-(chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide | 14 May, 2040 | Active |
| US11504333 | Pharmaceutical composition | 29 Dec, 2038 | Active |
| US11723901 | Uses of piperidinyl-indole derivatives | 30 Aug, 2038 | Active |
| US12285422 | Uses of piperidinyl-indole derivatives | 30 Aug, 2038 | Active |
| US11504333 | Pharmaceutical composition | 29 Jun, 2038 | Active |
| US10722471 | Galenic formulations of organic compounds | 02 Feb, 2037 | Active |
| US10851377 | Methods and compositions for treating a proprotein convertase subtilisin kexin (PCSK9) gene-associated disorder | 25 Aug, 2036 | Active |
| US11944602 | Treatment of autoimmune disease in a patient receiving additionally a beta-blocker | 23 Apr, 2036 | Active |
| US10799506 | Ribociclib tablet | 14 Apr, 2036 | Active |
| US12064434 | Ribociclib tablet | 14 Apr, 2036 | Active |
| US12109277 | Apparatus and method for penetrating and enlarging adjacent tissue layers | 09 Mar, 2036 | Active |
| US11951190 | Use of labeled inhibitors of prostate specific membrane antigen (PSMA), as agents for the treatment of prostate cancer | 12 Nov, 2035 | Active |
| US10398791 | Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer | 17 Oct, 2034 | Active |
| US10125369 | PCSK9 iRNA compositions and methods of use thereof | 18 Aug, 2034 | Active |
| US10093663 | Piperidinyl-indole derivatives complement factor B inhibitors and uses thereof | 14 Jul, 2034 | Active |
| US9682968 | Piperidinyl-indole derivatives complement factor B inhibitors and uses thereof | 14 Jul, 2034 | Active |
| US10016393 | Stabilized pharmaceutical dosage forms comprising atrasentan | 07 Jul, 2034 | Active |
| US9364458 | Stabilized pharmaceutical dosage forms comprising atrasentan | 07 Jul, 2034 | Active |
| US10869869 | Method of adjuvant cancer treatment | 28 Feb, 2034 | Active |
| US10869869 | Method of adjuvant cancer treatment | 30 Aug, 2033 | Active |
| US8829195 | Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 | 13 May, 2033 | Active |
| US8227462 | Pyrrolidine-1,2-dicarboxamide derivatives | 29 Apr, 2033 | Active |
| US9061029 | Method of treating proliferative disorders and other pathological conditions mediated by Bcr-Abl, c-Kit, DDR1, DDR2 or PDGF-R kinase activity | 07 Oct, 2032 | Active |
| US9592208 | Formulations comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol | 30 Sep, 2032 | Active |
| US8580304 | Pharmaceutical composition | 28 Jul, 2032 | Active |
| US9155706 | Pharmaceutical composition | 28 Jul, 2032 | Active |
| US9271941 | Pharmaceutical composition | 28 Jul, 2032 | Active |
| US9399021 | Pharmaceutical composition | 28 Jul, 2032 | Active |
| US9061029 | Method of treating proliferative disorders and other pathological conditions mediated by Bcr-Abl, c-Kit, DDR1, DDR2 or PDGF-R kinase activity | 07 Apr, 2032 | Active |
| US9592208 | Formulations comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol | 30 Mar, 2032 | Active |
| US11874283 | Method and compositions for the treatment and detection of endothelin-1 related kidney diseases | 18 Feb, 2032 | Active |
| US8703787 | Methods of using ALK inhibitors | 02 Feb, 2032 | Active |
| US8580304 | Pharmaceutical composition | 28 Jan, 2032 | Active |
| US9155706 | Pharmaceutical composition | 28 Jan, 2032 | Active |
| US9271941 | Pharmaceutical composition | 28 Jan, 2032 | Active |
| US9399021 | Pharmaceutical composition | 28 Jan, 2032 | Active |
| US9309229 | Crystalline forms of 5-chloro-N2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2, 4-diamine | 18 Jan, 2032 | Active |
| US12071402 | Immunosuppressant formulations | 05 Jan, 2032 | Active |
| US9193732 | Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-D]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof | 09 Nov, 2031 | Active |
| US9868739 | Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof | 09 Nov, 2031 | Active |
| US8703781 | Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors | 15 Apr, 2031 | Active |
| US8952018 | Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors | 15 Apr, 2031 | Active |
| US8415355 | Pyrrolopyrimidine compounds and their uses | 13 Mar, 2031 | Active |
| US8575146 | Pharmaceutical uses of staurosporine derivatives | 02 Dec, 2030 | Active |
| US8492441 | Dosage regimen of an S1P receptor agonist | 30 Nov, 2030 | Active |
| US8703781 | Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors | 15 Oct, 2030 | Active |
| US8952018 | Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors | 15 Oct, 2030 | Active |
| US7994185 | Benzene sulfonamide thiazole and oxazole compounds | 20 Jul, 2030 | Active |
| US8415345 | Benzene sulfonamide thiazole and oxazole compounds | 20 Jul, 2030 | Active |
| US8039474 | 2,3,4,9-tetrahydro-1H-carbazole derivatives as CRTH2 receptor antagonists | 29 Jun, 2030 | Active |
| US8039479 | Compounds and compositions as protein kinase inhibitors | 29 Jun, 2030 | Active |
| US8685980 | Pyrrolopyrimidine compounds and their uses | 25 May, 2030 | Active |
| US7994185 | Benzene sulfonamide thiazole and oxazole compounds | 20 Jan, 2030 | Active |
| US8415345 | Benzene sulfonamide thiazole and oxazole compounds | 20 Jan, 2030 | Active |
| US8613949 | Galenical formulations of organic compounds | 21 Dec, 2029 | Active |
| US8106022 | Carbohydrate conjugates as delivery agents for oligonucleotides | 12 Dec, 2029 | Active |
| US8962630 | Pyrrolopyrimidine compounds and their uses | 09 Dec, 2029 | Active |
| US9233956 | Benzene sulfonamide thiazole and oxazole compounds | 04 Nov, 2029 | Active |
| US8178582 | Pharmaceutical compositions having desirable bioavailability | 10 Oct, 2029 | Active |
| US8722735 | Pharmaceutical compositions having desirable bioavailability | 10 Oct, 2029 | Active |
| US8821927 | Pharmaceutical composition | 18 Sep, 2029 | Active |
| US8476268 | Pyrrolidine-1,2-dicarboxamide derivatives | 10 Sep, 2029 | Active |
| US9416136 | Pyrrolopyrimidine compounds and their uses | 20 Aug, 2029 | Active |
| US8754123 | Pharmaceutical compositions having desirable bioavailability | 19 May, 2029 | Active |
| US9233956 | Benzene sulfonamide thiazole and oxazole compounds | 04 May, 2029 | Active |
| US9144561 | Pharmaceutical compositions having desirable bioavailability | 13 Mar, 2029 | Active |
| US8163904 | Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-Benzamide | 23 Feb, 2029 | Active |
| US10806791 | Carbohydrate conjugates as delivery agents for oligonucleotides | 04 Dec, 2028 | Active |
| US8828956 | Carbohydrate conjugates as delivery agents for oligonucleotides | 04 Dec, 2028 | Active |
| US9370582 | Carbohydrate conjugates as delivery agents for oligonucleotides | 04 Dec, 2028 | Active |
| US8182838 | Dry powder composition comprising co-jet milled particles for pulmonary inhalation | 20 Oct, 2028 | Active |
| US8479730 | Inhaler device | 11 Oct, 2028 | Active |
| US7973031 | Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity | 09 Oct, 2028 | Active |
| US7939519 | Immunosuppresant compounds and compositions | 27 Aug, 2028 | Active |
| US10131907 | Glycoconjugates of RNA interference agents | 24 Aug, 2028 | Active |
| US8163904 | Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-Benzamide | 23 Aug, 2028 | Active |
| US8623819 | Therapy for complications of diabetes | 22 Aug, 2028 | Active |
| US11369590 | PSMA binding ligand-linker conjugates and methods for using | 15 Aug, 2028 | Active |
| US10406240 | PSMA binding ligand-linker conjugates and methods for using | 15 Aug, 2028 | Active |
| US11318121 | PSMA binding ligand-linker conjugates and methods for using | 15 Aug, 2028 | Active |
| US9006224 | Neuroendocrine tumor treatment | 01 Jul, 2028 | Active |
| US8324225 | Pyrrolopyrimidine compounds and their uses | 17 Jun, 2028 | Active |
| US7964592 | 2,4-di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders | 29 Apr, 2028 | Active |
| US8293756 | Pharmaceutical compositions comprising nilotinib hydrochloride monohydrate | 25 Mar, 2028 | Active |
| US7932241 | Pharmaceutical products comprising bisphosphonates | 05 Feb, 2028 | Active |
| US8052993 | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) | 01 Feb, 2028 | Active |
| US8052994 | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) | 01 Feb, 2028 | Active |
| US8052995 | 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine) | 01 Feb, 2028 | Active |
| US8062665 | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1 ,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) | 01 Feb, 2028 | Active |
| US8071129 | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) | 01 Feb, 2028 | Active |
| US8828430 | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) | 01 Feb, 2028 | Active |
| US8222222 | Compositions and methods for inhibiting expression of the PCSK9 gene | 29 Dec, 2027 | Active |
| US10543179 | Dosage regimen of an S1P receptor modulator | 25 Dec, 2027 | Active |
| US9187405 | S1P receptor modulators for treating relasping-remitting multiple sclerosis | 25 Dec, 2027 | Active |
| US7378423 | Pyrimidine compound and medical use thereof | 29 Nov, 2027 | Active |
| US8377921 | Compounds and compositions as protein kinase inhibitors | 20 Nov, 2027 | Active |
| US8399450 | Compounds and compositions as protein kinase inhibitors | 20 Nov, 2027 | Active |
| US8293756 | Pharmaceutical compositions comprising nilotinib hydrochloride monohydrate | 25 Sep, 2027 | Active |
| US8052993 | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) | 01 Aug, 2027 | Active |
| US8052994 | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) | 01 Aug, 2027 | Active |
| US8052995 | 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine) | 01 Aug, 2027 | Active |
| US8062665 | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1 ,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) | 01 Aug, 2027 | Active |
| US8071129 | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) | 01 Aug, 2027 | Active |
| US8828430 | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) | 01 Aug, 2027 | Active |
| US9187405 | S1P receptor modulators for treating relasping-remitting multiple sclerosis | 25 Jun, 2027 | Active |
| US7378423 | Pyrimidine compound and medical use thereof | 29 May, 2027 | Active |
| US8877938 | Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations | 27 May, 2027 | Active |
| US8809292 | Compositions and methods for inhibiting expression of the PCSK9 gene | 10 May, 2027 | Active |
| US8389537 | Salts of 4-methyl N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide | 18 Jan, 2027 | Active |
| US8415363 | Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide | 18 Jan, 2027 | Active |
| US8501760 | Pharmaceutical compositions comprising nilotinib or its salt | 18 Jan, 2027 | Active |
| US9388134 | Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl)-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations | 08 Nov, 2026 | Active |
| US8324283 | Solid pharmaceutical compositions comprising a SIP receptor agonist and a sugar alcohol | 29 Sep, 2026 | Active |
| US8389537 | Salts of 4-methyl N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide | 18 Jul, 2026 | Active |
| US8415363 | Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide | 18 Jul, 2026 | Active |
| US8501760 | Pharmaceutical compositions comprising nilotinib or its salt | 18 Jul, 2026 | Active |
| US8168616 | Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension | 03 Jul, 2026 | Active |
| US8410131 | Cancer treatment | 01 May, 2026 | Active |
| US7893074 | 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders | 25 Apr, 2026 | Active |
| US8324283 | Solid pharmaceutical compositions comprising a SIP receptor agonist and a sugar alcohol | 29 Mar, 2026 | Active |
| US7547719 | 3′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine) | 13 Jan, 2026 | Active |
| US8835443 | Pyrimidine compound and medical use thereof | 10 Dec, 2025 | Active |
| US8324189 | Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases | 29 Nov, 2025 | Active |
| US8410131 | Cancer treatment | 01 Nov, 2025 | Active |
| US7547719 | 3′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine) | 13 Jul, 2025 | Active |
| US8835443 | Pyrimidine compound and medical use thereof | 10 Jun, 2025 | Expired |
| US8324189 | Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases | 29 May, 2025 | Expired |
| US6878721 | Beta2-adrenoceptor agonists | 25 Feb, 2025 | Expired |
| US8101659 | Methods of treatment and pharmaceutical composition | 15 Jan, 2025 | Expired |
| US11530408 | Therapeutic compositions | 18 May, 2024 | Expired |
| US10273477 | Therapeutic compositions | 08 Mar, 2024 | Expired |
| US10669544 | Therapeutic compositions | 08 Mar, 2024 | Expired |
| US9708615 | Therapeutic compositions | 08 Mar, 2024 | Expired |
| US7169791 | Inhibitors of tyrosine kinases | 04 Jan, 2024 | Expired |
| US9708610 | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation | 01 Jan, 2024 | Expired |
| US7795293 | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) | 21 Nov, 2023 | Expired |
| US8475839 | Solid dosage forms of valsartan, amlodipine and hydrochlorothiazide and method of making the same | 16 Nov, 2023 | Expired |
| US10266825 | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation | 04 Nov, 2023 | Expired |
| US11078485 | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation | 04 Nov, 2023 | Expired |
| US7105530 | Pyrimidineamines as angiogenesis modulators | 19 Oct, 2023 | Expired |
| US7589079 | Crystalline and amorphous forms of beta-L-2′-deoxythymidine | 11 Sep, 2023 | Expired |
| US7858594 | Crystalline and amorphous forms of beta-L-2′-deoxythymidine | 11 Sep, 2023 | Expired |
| US7977376 | Olopatadine formulations for topical nasal administration | 02 Aug, 2023 | Expired |
| US7169791 | Inhibitors of tyrosine kinases | 04 Jul, 2023 | Expired |
| US7795293 | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) | 21 May, 2023 | Expired |
| US7160870 | Thrombopoietin mimetics | 20 May, 2023 | Expired |
| US8183295 | Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic | 16 May, 2023 | Expired |
| US8101599 | Pharmaceutical composition containing anti-hypertensive agents | 16 May, 2023 | Expired |
| US8475839 | Solid dosage forms of valsartan, amlodipine and hydrochlorothiazide and method of making the same | 16 May, 2023 | Expired |
| US8399508 | Olopatadine formulations for topical nasal administration | 17 Mar, 2023 | Expired |
| US8232383 | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) | 20 Feb, 2023 | Expired |
| US7977376 | Olopatadine formulations for topical nasal administration | 02 Feb, 2023 | Expired |
| US8188276 | 2,4-pyrimidinediamine compounds and their uses | 31 Jan, 2023 | Expired |
| US8835430 | 2,4-pyrimidinediamine compounds and their uses | 31 Jan, 2023 | Expired |
| US9018204 | 2,4-pyrimidinediamine compounds and their uses | 31 Jan, 2023 | Expired |
| US9416112 | 2,4-pyrimidinediamine compounds and their uses | 31 Jan, 2023 | Expired |
| US7160870 | Thrombopoietin mimetics | 20 Nov, 2022 | Expired |
| US8222244 | Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity | 29 Oct, 2022 | Expired |
| US8399508 | Olopatadine formulations for topical nasal administration | 17 Sep, 2022 | Expired |
| US8436010 | Treatment of solid tumors with rapamycin derivatives | 22 Aug, 2022 | Expired |
| US8778962 | Treatment of solid tumors with rapamycin derivatives | 18 Aug, 2022 | Expired |
| US10590418 | Methods and compositions for RNAi mediated inhibition of gene expression in mammals | 19 Jul, 2022 | Expired |
| US6958335 | Treatment of gastrointestinal stromal tumors | 19 Jun, 2022 | Expired |
| US8546143 | Compositions and methods for inhibiting expression of a target gene | 23 Apr, 2022 | Expired |
| US9074213 | Compositions and methods for inhibiting expression of a target gene | 09 Mar, 2022 | Expired |
| US8436010 | Treatment of solid tumors with rapamycin derivatives | 22 Feb, 2022 | Expired |
| US8778962 | Treatment of solid tumors with rapamycin derivatives | 18 Feb, 2022 | Expired |
| US6958335 | Treatment of gastrointestinal stromal tumors | 19 Dec, 2021 | Expired |
| US7262203 | Pyrimidineamines as angiogenesis modulators | 19 Dec, 2021 | Expired |
| US8114885 | Chemical compounds | 19 Dec, 2021 | Expired |
| US7332481 | Thrombopoietin mimetics | 24 Nov, 2021 | Expired |
| US7452874 | Thrombopoietin mimetics | 24 Nov, 2021 | Expired |
| US7473686 | Thrombopoietin mimetics | 24 Nov, 2021 | Expired |
| US7790704 | Thrombopoietin mimetics | 24 Nov, 2021 | Expired |
| US7157466 | Quinazoline ditosylate salt compounds | 19 Nov, 2021 | Expired |
| US8618174 | Synergistic combinations comprising a renin inhibitor for cardiovascular diseases | 15 Nov, 2021 | Expired |
| US7736670 | Method of making particles for use in a pharmaceutical composition | 27 Jun, 2021 | Expired |
| US8048451 | Pharmaceutical compositions for inhalation | 27 Jun, 2021 | Expired |
| US8303991 | Method of making particles for use in a pharmaceutical composition | 27 Jun, 2021 | Expired |
| US8435567 | Pharmaceutical compositions of hydrophobic surface-modified active substance microparticles for inhalation | 27 Jun, 2021 | Expired |
| US8580306 | Particles for use in a pharmaceutical composition | 27 Jun, 2021 | Expired |
| US8956661 | Method of making composite particles for use in pharmaceutical compositions and composite particles and compositions thereof | 27 Jun, 2021 | Expired |
| US9931304 | Method of making particles for use in a pharmaceutical composition | 27 Jun, 2021 | Expired |
| US9962338 | Method of making particles for use in a pharmaceutical composition | 27 Jun, 2021 | Expired |
| US8119148 | Suspension comprising oxcarbazepine | 19 Jun, 2021 | Expired |
| US7332481 | Thrombopoietin mimetics | 24 May, 2021 | Expired |
| US7452874 | Thrombopoietin mimetics | 24 May, 2021 | Expired |
| US7473686 | Thrombopoietin mimetics | 24 May, 2021 | Expired |
| US7790704 | Thrombopoietin mimetics | 24 May, 2021 | Expired |
| US7229607 | Treatment of respiratory disease | 09 Apr, 2021 | Expired |
| US8029768 | Treatment of respiratory diseases | 09 Apr, 2021 | Expired |
| US7153964 | Pyrimidine compounds | 26 Feb, 2021 | Expired |
| US8119148 | Suspension comprising oxcarbazepine | 19 Dec, 2020 | Expired |
| US6887459 | Aerosol composition comprising formoterol | 28 Nov, 2020 | Expired |
| US6569837 | β-L-2′-deoxy pyrimidine nucleosides for the treatment of hepatitis B | 25 Oct, 2020 | Expired |
| US6713485 | Heterocyclic compounds | 29 Sep, 2020 | Expired |
| US6559188 | Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes | 15 Sep, 2020 | Expired |
| US6878749 | Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes | 15 Sep, 2020 | Expired |
| US7297703 | Macrolides | 06 Jun, 2020 | Expired |
| US8067437 | Beta-2-adrenoreceptor agonists | 02 Jun, 2020 | Expired |
| US8658673 | BETA2-adrenoreceptor agonists | 02 Jun, 2020 | Expired |
| US8796307 | Beta2-adrenoreceptor agonists | 02 Jun, 2020 | Expired |
| US7820694 | Beta-2-adrenoreceptor agonists | 02 Jun, 2020 | Expired |
| US8283362 | Beta-2-adrenoreceptor agonists | 02 Jun, 2020 | Expired |
| US5665772 | O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants | 09 Mar, 2020 | Expired |
| US7297703 | Macrolides | 06 Dec, 2019 | Expired |
| US7741338 | Macrolides | 06 Dec, 2019 | Expired |
| US6894051 | Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use | 23 Nov, 2019 | Expired |
| US5665772 | O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants | 09 Sep, 2019 | Expired |
| US5604229 | 2-amino-1,3-propanediol compound and immunosuppressant | 18 Aug, 2019 | Expired |
| US6395716 | β-L-2′-deoxy-nucleosides for the treatment of hepatitis B | 10 Aug, 2019 | Expired |
| US6444652 | β-L-2'-deoxy-nucleosides for the treatment of hepatitis B | 10 Aug, 2019 | Expired |
| US6566344 | β-L-2′-deoxy-nucleosides for the treatment of hepatitis B | 10 Aug, 2019 | Expired |
| US7795238 | β-L-2′-deoxy-nucleosides for the treatment of hepatitis B | 10 Aug, 2019 | Expired |
| US7544799 | Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use | 16 Jul, 2019 | Expired |
| USRE43932 | Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use | 16 Jul, 2019 | Expired |
| US6395728 | Method of treatment and pharmaceutical composition | 08 Jul, 2019 | Expired |
| US6894051 | Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use | 23 May, 2019 | Expired |
| US6280959 | Metal complexes | 30 Apr, 2019 | Expired |
| US6465504 | Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators | 05 Apr, 2019 | Expired |
| US6488027 | Powder inhaler | 08 Mar, 2019 | Expired |
| US5604229 | 2-amino-1,3-propanediol compound and immunosuppressant | 18 Feb, 2019 | Expired |
| US7544799 | Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use | 16 Jan, 2019 | Expired |
| USRE43932 | Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use | 16 Jan, 2019 | Expired |
| US6727256 | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors | 08 Jan, 2019 | Expired |
| US8513262 | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors | 08 Jan, 2019 | Expired |
| US6280959 | Metal complexes | 30 Oct, 2018 | Expired |
| US7037525 | Oxacarbazepine film-coated tablets | 12 Aug, 2018 | Expired |
| US5559111 | δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amides | 21 Jul, 2018 | Expired |
| US6528678 | Phosgene-free process for preparing carbamates | 24 Apr, 2018 | Expired |
| US6582678 | Carrier particles for use in dry powder inhalers | 24 Apr, 2018 | Expired |
| US6306900 | Enteric coated pharmaceutical compositions | 27 Feb, 2018 | Expired |
| US7037525 | Oxacarbazepine film-coated tablets | 12 Feb, 2018 | Expired |
| US6239124 | Pharmaceutical compositions for the treatment of transplant rejection or autoimmune or inflammatory conditions comprising cyclosporin A and 40-0-(2-hydroxyethyl)-rapamycin | 11 Feb, 2018 | Expired |
| US6455518 | Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-O-(2-hydroxyethyl)-rapamycin | 29 Jan, 2018 | Expired |
| US6294197 | Solid oral dosage forms of valsartan | 18 Dec, 2017 | Expired |
| US6641841 | Tablet composition | 14 Nov, 2017 | Expired |
| US6844008 | Tablet composition | 14 Nov, 2017 | Expired |
| US6004565 | Compositions and methods of using compositions with accelerated lymphocyte homing immunosuppressive properties | 23 Sep, 2017 | Expired |
| US6239124 | Pharmaceutical compositions for the treatment of transplant rejection or autoimmune or inflammatory conditions comprising cyclosporin A and 40-0-(2-hydroxyethyl)-rapamycin | 11 Aug, 2017 | Expired |
| US6455518 | Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-O-(2-hydroxyethyl)-rapamycin | 29 Jul, 2017 | Expired |
| US6391874 | Fused heterocyclic compounds as protein tyrosine kinase inhibitors | 11 Jul, 2017 | Expired |
| US6828320 | Heterocyclic compounds | 11 Jul, 2017 | Expired |
| US6596750 | Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators | 24 Jun, 2017 | Expired |
| US6294197 | Solid oral dosage forms of valsartan | 18 Jun, 2017 | Expired |
| US5972990 | Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims | 26 Apr, 2017 | Expired |
| US6025391 | Enteric-coated pharmaceutical compositions of mycophenolate | 10 Apr, 2017 | Expired |
| US6172107 | Entric-coated pharmaceutical compositions | 10 Apr, 2017 | Expired |
| US5922338 | Polyol esters, their preparation and use in depot forms of pharmacologically active agents | 13 Jan, 2017 | Expired |
| US5922682 | Polyol esters, their preparation and use in depot forms of pharmacologically active agents | 13 Jan, 2017 | Expired |
| US6004973 | Pharmaceutical compositions comprising rafamycin coprecipitates | 12 Jan, 2017 | Expired |
| US5972990 | Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims | 26 Oct, 2016 | Expired |
| US5922338 | Polyol esters, their preparation and use in depot forms of pharmacologically active agents | 13 Jul, 2016 | Expired |
| US5922682 | Polyol esters, their preparation and use in depot forms of pharmacologically active agents | 13 Jul, 2016 | Expired |
| US6004973 | Pharmaceutical compositions comprising rafamycin coprecipitates | 12 Jul, 2016 | Expired |
| US5840763 | Treatment of a latent infection of herpes viruses | 01 Mar, 2016 | Expired |
| US5916893 | Treatment of a latent infection of herpes virus | 01 Mar, 2016 | Expired |
| US6521260 | Carrier particles for use in dry powder inhalers | 31 Jan, 2016 | Expired |
| US5753618 | Somatostatin analogue composition and use in treating breast cancer | 19 Nov, 2015 | Expired |
| US5840763 | Treatment of a latent infection of herpes viruses | 01 Sep, 2015 | Expired |
| US5916893 | Treatment of a latent infection of herpes virus | 01 Sep, 2015 | Expired |
| US5521184 | Pyrimidine derivatives and processes for the preparation thereof | 04 Jul, 2015 | Expired |
| US5753618 | Somatostatin analogue composition and use in treating breast cancer | 19 May, 2015 | Expired |
| US5688530 | Sustained release formulations of water soluble peptides | 18 May, 2015 | Expired |
| US5866581 | Penciclovir for the treatment of post therapeutic neuralgia | 04 Apr, 2015 | Expired |
| US6124304 | Penciclovir for the treatment of zoster associated pain | 04 Apr, 2015 | Expired |
| US5521184 | Pyrimidine derivatives and processes for the preparation thereof | 04 Jan, 2015 | Expired |
| US5639480 | Sustained release formulations of water soluble peptides | 17 Dec, 2014 | Expired |
| US5688530 | Sustained release formulations of water soluble peptides | 18 Nov, 2014 | Expired |
| US5677331 | Antimalarial compositions | 14 Oct, 2014 | Expired |
| US5866581 | Penciclovir for the treatment of post therapeutic neuralgia | 04 Oct, 2014 | Expired |
| US6124304 | Penciclovir for the treatment of zoster associated pain | 04 Oct, 2014 | Expired |
| US5985321 | Soft gelatin capsule manufacture | 26 Sep, 2014 | Expired |
| US5639480 | Sustained release formulations of water soluble peptides | 17 Jun, 2014 | Expired |
| US6440990 | O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants | 24 Mar, 2014 | Expired |
| US5602176 | Phenyl carbamate | 11 Feb, 2014 | Expired |
| US5538739 | Sustained release formulations of water soluble peptides | 23 Jan, 2014 | Expired |
| US5441958 | Ophthalmic compositions comprising emedastine and methods for their use | 08 Dec, 2013 | Expired |
| US6440990 | O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants | 24 Sep, 2013 | Expired |
| US5538739 | Sustained release formulations of water soluble peptides | 23 Jul, 2013 | Expired |
| US4939130 | Substituted alkanediphosphonic acids and pharmaceutical use | 02 Mar, 2013 | Expired |
| US5488150 | Crystals of N-(trans-4-isopropylcyclohexycarbonyl)-D-phenylalanine and methods for preparing them | 30 Jan, 2013 | Expired |
| US5463116 | Crystals of N- (trans-4-isopropylcyclohexlycarbonyl)-D-phenylalanine and methods for preparing them | 21 Oct, 2012 | Expired |
| US5457126 | Use of lodoxamide to treat ophthalmic allergic conditions | 10 Oct, 2012 | Expired |
| US5399578 | Acyl compounds | 21 Sep, 2012 | Expired |
| US4939130 | Substituted alkanediphosphonic acids and pharmaceutical use | 02 Sep, 2012 | Expired |
| US5442049 | Oligonucleotides for modulating the effects of cytomegalovirus infections | 15 Aug, 2012 | Expired |
| US5595978 | Composition and method for treatment of CMV retinites | 15 Aug, 2012 | Expired |
| US4948807 | Phenyl carbamates | 14 Aug, 2012 | Expired |
Latest Legal Activities on Novartis's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Novartis.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Expire Patent
Critical
| 01 Jul, 2024 | US8188276 (Litigated) |
|
Expire Patent
Critical
| 24 Jun, 2024 | US8183295 |
| Surcharge for Late Payment, Large Entity | 11 Jun, 2024 | US10806791 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 11 Jun, 2024 | US10806791 |
|
Maintenance Fee Reminder Mailed
Critical
| 10 Jun, 2024 | US10806791 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 05 Jun, 2024 | US10869869 |
|
Expire Patent
Critical
| 03 Jun, 2024 | US8168616 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 03 Jun, 2024 | US10851377 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 22 May, 2024 | US8324225 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 22 May, 2024 | US8324225 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 22 May, 2024 | US8324189 |
|
Expire Patent
Critical
| 22 Apr, 2024 | US10590418 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 10 Apr, 2024 | US8293756 |
|
Maintenance Fee Reminder Mailed
Critical
| 08 Apr, 2024 | US9416112 |
| Court Processing Terminated | 03 Apr, 2024 | US7973031 |
Novartis's Drug Patent Litigations
Novartis's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Apr 05, 1995, against patent number US5922682. The petitioner , challenged the validity of this patent, with BRICH et al as the respondent. Click below to track the latest information on how companies are challenging Novartis's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US8101659 | August, 2020 |
Terminated-Denied
(16 Feb, 2021)
| Novartis Pharmaceuticals Corporation | Biocon Pharma Limited |
| US9006224 | July, 2016 |
Final Written Decision
(05 Oct, 2020)
| Novartis AG | Par Pharmaceutical, Inc. et al. |
| US8410131 | June, 2017 |
Terminated-Settled
(03 Jun, 2019)
| Novartis Pharmaceuticals Corporation | Breckenridge Pharmaceutial, Inc. |
| US8410131 | January, 2018 |
Terminated-Settled
(03 Jun, 2019)
| Novartis Pharmaceuticals Corporation | Hikma Pharmaceuticals PLC |
| US9187405 | August, 2017 |
FWD Entered
(07 Aug, 2018)
| Novartis Pharmaceuticals Corporation | Actavis Elizabeth LLC |
| US9187405 | August, 2017 |
Terminated
(07 Aug, 2018)
| Novartis Pharmaceuticals Corporation | Sun Pharmaceutical Industries, Ltd. et al. |
| US9187405 | February, 2017 |
FWD Entered
(11 Jul, 2018)
| Novartis AG | Apotex Inc. |
| US5665772 | October, 2015 |
FWD Entered
(11 Jan, 2018)
| Novartis AG | Par Pharmaceutical, Inc. |
| US9006224 | March, 2017 |
Final Written Decision
(25 Sep, 2017)
| Novartis AG | Argentum Pharmaceuticals LLC et al. |
| US9006224 | March, 2017 |
Terminated-Settled
(25 Sep, 2017)
| Novartis AG | West-Ward Pharmaceuticals International Limited |
| US9187405 | June, 2017 |
FWD Entered
(17 Aug, 2017)
| Novartis AG | Argentum Pharmaceuticals LLC |
| US9006224 | July, 2016 |
Terminated-Denied
(13 Feb, 2017)
| Novartis AG | Roxane Laboratories, Inc. |
| US5665772 | May, 2016 |
FWD Entered
(27 Oct, 2016)
| Novartis AG | BRECKENRIDGE PHARMACEUTICAL, INC. |
| US5665772 | May, 2016 |
Terminated-Denied
(27 Oct, 2016)
| Novartis AG | Par Pharmaceutical, Inc. |
| US5665772 | May, 2016 |
FWD Entered
(27 Oct, 2016)
| Novartis AG | Roxane Laboratories, Inc. |
| US5665772 | May, 2016 |
Terminated-Denied
(27 Oct, 2016)
| Novartis AG | Breckenridge Pharmaceutical, Inc. |
| US6455518 | October, 2015 |
Terminated-Denied
(28 Apr, 2016)
| Novartis AG | Par Pharmaceutical, Inc. |
| US7297703 | October, 2015 |
Terminated-Denied
(01 Apr, 2016)
| Novartis AG | Par Pharmaceutical, Inc. |
| US7741338 | October, 2015 |
Terminated-Denied
(01 Apr, 2016)
| Novartis AG | Par Pharmaceutical, Inc. |
| US8324283 | May, 2014 |
FWD Entered
(24 Sep, 2015)
| Novartis AG | TORRENT PHARMACEUTICALS LIMITED |
| US8324283 | December, 2014 |
Final Written Decision
(24 Sep, 2015)
| Novartis AG et al. | Apotex, Inc. et al. |
| US10590418 | April, 2012 |
Decision
(04 Mar, 2015)
| Mark A. Kay et al | |
| US8575146 | January, 2011 |
Decision
(22 Mar, 2013)
| Steven Coutre | |
| US6894051 | March, 2003 |
Decision
(24 Nov, 2003)
| JURG ZIMMERMANN et al | |
| US5972990 | January, 1 |
Decision
(12 Feb, 1999)
| PFEFFER et al | |
| US5922682 | April, 1995 |
Decision
(04 Jul, 1776)
| BRICH et al | |
Novartis Drug Patents' Oppositions Filed in EPO
Novartis drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on May 20, 2003, by Sirna Therapeutics, Inc.. This opposition was filed on patent number EP00910510A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP15177166A | May, 2023 | Synthon BV | Granted and Under Opposition |
| EP19174594A | May, 2023 | Brand Murray Fuller LLP | Granted and Under Opposition |
| EP15177166A | May, 2023 | Wuesthoff & Wuesthoff Patentanwälte PartG mbB | Granted and Under Opposition |
| EP19174594A | May, 2023 | STADA Arzneimittel AG | Granted and Under Opposition |
| EP15177166A | Mar, 2023 | neuraxpharm Arzneimittel GmbH | Granted and Under Opposition |
| EP15177166A | Jan, 2023 | Dr. Schön, Neymeyr & Partner Patentanwälte mbB | Granted and Under Opposition |
| EP15177166A | Jan, 2023 | BIOGARAN | Granted and Under Opposition |
| EP15177166A | Jan, 2023 | STADA Arzneimittel AG | Granted and Under Opposition |
| EP18155722A | Jan, 2023 | Generics [UK] Limited | Granted and Under Opposition |
| EP18155722A | Jan, 2023 | Ethypharm | Granted and Under Opposition |
| EP18155722A | Jan, 2023 | STADA Arzneimittel AG | Granted and Under Opposition |
| EP15177166A | Jan, 2023 | Bausch Health Ireland Limited | Granted and Under Opposition |
| EP15177166A | Dec, 2022 | Vivanta Generics s.r.o. / MSN Labratories Private Ltd. | Granted and Under Opposition |
| EP15177166A | Dec, 2022 | Heumann Pharma GmbH & Co. Generica KG | Granted and Under Opposition |
| EP15177166A | Dec, 2022 | Accord Healthcare Ltd | Granted and Under Opposition |
| EP15177166A | Nov, 2022 | A-med GmbH | Granted and Under Opposition |
| EP15177166A | Nov, 2022 | RAFARM S.A. | Granted and Under Opposition |
| EP15177166A | Nov, 2022 | Genepharm S.A. | Granted and Under Opposition |
| EP15177166A | Oct, 2022 | Elpen Pharmaceutical Co. Inc. | Granted and Under Opposition |
| EP15177166A | Oct, 2022 | Glenmark Pharmaceuticals Europe Ltd. | Granted and Under Opposition |
| EP15177166A | Oct, 2022 | Teva Pharmaceutical Industries Ltd | Granted and Under Opposition |
| EP15177166A | Oct, 2022 | Generics [UK] Limited | Granted and Under Opposition |
| EP15177166A | Oct, 2022 | Zentiva k.s. | Granted and Under Opposition |
| EP15177166A | Oct, 2022 | PHARMATHEN S.A. | Granted and Under Opposition |
| EP13835019A | Jun, 2022 | Generics [UK] Limited | Granted and Under Opposition |
| EP13835019A | Jun, 2022 | Teva Pharmaceutical Industries Ltd | Granted and Under Opposition |
| EP13835019A | Jun, 2022 | STADA Arzneimittel AG | Granted and Under Opposition |
| EP10176094A | Apr, 2021 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Granted and Under Opposition |
| EP10176094A | Apr, 2021 | betapharm Arzneimittel GmbH | Granted and Under Opposition |
| EP10176094A | Apr, 2021 | Krka, d.d., Novo mesto | Granted and Under Opposition |
| EP10176094A | Apr, 2021 | ZAKLADY FARMACEUTYCZNE POLPHARMA S.A. | Granted and Under Opposition |
| EP10176094A | Apr, 2021 | STADA Arzneimittel AG | Granted and Under Opposition |
| EP10176094A | Apr, 2021 | D Young & Co LLP | Granted and Under Opposition |
| EP10176094A | Apr, 2021 | Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi | Granted and Under Opposition |
| EP11849974A | Apr, 2021 | Generics [UK] Limited | Granted and Under Opposition |
| EP11849974A | Apr, 2021 | Teva Pharmaceutical Industries Ltd | Granted and Under Opposition |
| EP10176094A | Jan, 2021 | Generics [UK] Limited | Granted and Under Opposition |
| EP08798020A | Jul, 2020 | Boult Wade Tennant LLP | Revoked |
| EP08798020A | Jul, 2020 | Orano Med | Revoked |
| EP18155724A | Jun, 2020 | ARROW GENERIQUES | Granted and Under Opposition |
| EP18155724A | May, 2020 | Teva Pharmaceutical Industries Ltd. | Granted and Under Opposition |
| EP18155724A | May, 2020 | Zentiva k.s. | Granted and Under Opposition |
| EP18155724A | May, 2020 | Generics [UK] Ltd | Granted and Under Opposition |
| EP18155724A | Apr, 2020 | PUREN Pharma GmbH & Co. KG | Granted and Under Opposition |
| EP10824148A | Mar, 2020 | Generics (UK) Ltd | Opposition rejected |
| EP10824148A | Mar, 2020 | Teva Pharmaceutical Industries Ltd | Opposition rejected |
| EP18155644A | Feb, 2020 | ARROW GENERIQUES | Granted and Under Opposition |
| EP18155644A | Feb, 2020 | Teva Pharmaceutical Industries Ltd | Granted and Under Opposition |
| EP18155644A | Feb, 2020 | Generics [UK] Limited | Granted and Under Opposition |
| EP18155724A | Feb, 2020 | Ethypharm | Granted and Under Opposition |
| EP18155644A | Jan, 2020 | Dr. Reddy's Laboratories Limited | Granted and Under Opposition |
| EP18155724A | Sep, 2019 | BIOGARAN | Granted and Under Opposition |
| EP18155644A | Sep, 2019 | Zentiva Pharma GmbH | Granted and Under Opposition |
| EP16186041A | Sep, 2019 | STADA Arzneimittel AG | Granted and Under Opposition |
| EP16186041A | Sep, 2019 | Generics [UK] Ltd | Granted and Under Opposition |
| EP16186041A | Sep, 2019 | Accord Healthcare Ltd | Granted and Under Opposition |
| EP16186041A | Sep, 2019 | Zentiva k.s. | Granted and Under Opposition |
| EP16186041A | Aug, 2019 | Teva Pharmaceutical Industries Ltd | Granted and Under Opposition |
| EP16186041A | Aug, 2019 | Synthon B.V. | Granted and Under Opposition |
| EP18155724A | Aug, 2019 | Dr. Reddy's Laboratories / Betapharm Arzneimittel GmbH | Granted and Under Opposition |
| EP18155724A | Aug, 2019 | Accord Healthcare Ltd | Granted and Under Opposition |
| EP18155724A | Aug, 2019 | STADA Arzneimittel AG | Granted and Under Opposition |
| EP18155644A | Jul, 2019 | Accord Healthcare Ltd | Granted and Under Opposition |
| EP10174983A | Jul, 2019 | Zentiva France | Revoked |
| EP18155644A | Jul, 2019 | Ethypharm | Granted and Under Opposition |
| EP18155644A | Jul, 2019 | BIOGARAN | Granted and Under Opposition |
| EP16186041A | Jun, 2019 | Ethypharm | Granted and Under Opposition |
| EP18155644A | May, 2019 | STADA Arzneimittel AG | Granted and Under Opposition |
| EP16167355A | May, 2019 | Teva Pharmaceutical Industries Ltd | Opposition rejected |
| EP16167355A | Apr, 2019 | Generics (UK) Ltd | Opposition rejected |
| EP04727320A | Dec, 2018 | Teva UK Limited | Revoked |
| EP10181354A | Dec, 2018 | Teva UK Limited | Patent maintained as amended |
| EP11806079A | Apr, 2018 | Generics (UK) Ltd | Revoked |
| EP11806079A | Apr, 2018 | Teva Pharmaceutical Industries Ltd | Revoked |
| EP14164259A | Mar, 2018 | Generics (UK) Ltd | Revoked |
| EP15202422A | Feb, 2018 | actrevo GmbH | Granted and Under Opposition |
| EP15202422A | Feb, 2018 | Generics [UK] Limited (trading as Mylan) | Granted and Under Opposition |
| EP15202422A | Feb, 2018 | ZAKLADY FARMACEUTYCZNE POLPHARMA S.A. | Granted and Under Opposition |
| EP15202422A | Feb, 2018 | Bausch & Lomb Incorporated | Granted and Under Opposition |
| EP15202422A | Feb, 2018 | Instone, Terry/Appleyard Lees IP LLP/Read, Howard | Granted and Under Opposition |
| EP12193597A | Jan, 2018 | Generics [UK] Limited (trading as Mylan) | Granted and Under Opposition |
| EP12193597A | Jan, 2018 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Granted and Under Opposition |
| EP14164565A | Dec, 2017 | Generics (U.K.) Limited | Revoked |
| EP14164565A | Dec, 2017 | Ethypharm | Revoked |
| EP06025389A | Dec, 2017 | Silence Therapeutics GmbH | Revoked |
| EP10173956A | Nov, 2017 | D Young & Co LLP | Patent maintained as amended |
| EP10174985A | Apr, 2017 | Intas Pharmaceuticals Ltd. | Revoked |
| EP10174985A | Apr, 2017 | Generics [UK] Ltd | Revoked |
| EP10174985A | Apr, 2017 | Wittkopp, Alexander | Revoked |
| EP10174985A | Apr, 2017 | STADA Arzneimittel AG | Revoked |
| EP10174985A | Apr, 2017 | Teva Pharmaceutical Industries Ltd | Revoked |
| EP10174985A | Apr, 2017 | KRKA, d.d., Novo mesto | Revoked |
| EP10174985A | Apr, 2017 | Fresenius Kabi Deutschland GmbH | Revoked |
| EP10174985A | Apr, 2017 | Synthon Biopharmaceuticals B.V. | Revoked |
| EP10011217A | Apr, 2017 | Silence Therapeutics GmbH | Opposition rejected |
| EP09743378A | Dec, 2016 | STADA Arzneimittel AG | Opposition rejected |
| EP10781781A | Nov, 2016 | Generics (U.K.) Limited | Granted and Under Opposition |
| EP10781781A | Nov, 2016 | Hamm&Wittkopp Patentanwälte PartmbB | Granted and Under Opposition |
| EP10781781A | Nov, 2016 | Teva Pharmaceutical Industries Ltd | Granted and Under Opposition |
| EP10781781A | Nov, 2016 | Intas Pharmaceuticals Ltd. | Granted and Under Opposition |
| EP10781781A | Nov, 2016 | Fresenius Kabi Deutschland GmbH | Granted and Under Opposition |
| EP07840632A | Sep, 2016 | Galenicum Health S.L. | Revoked |
| EP07840632A | Sep, 2016 | Generics (U.K.) Limited | Revoked |
| EP07840632A | Sep, 2016 | Teva Pharmaceutical Industries Ltd | Revoked |
| EP07840632A | Sep, 2016 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Revoked |
| EP07840632A | Sep, 2016 | ZBM Patents ApS | Revoked |
| EP07820560A | Jun, 2016 | Fresenius Kabi Deutschland GmbH | Patent maintained as amended |
| EP07820560A | Jun, 2016 | medac Gesellschaft für klinische Spezialpräparate mbH | Patent maintained as amended |
| EP07820560A | Jun, 2016 | Strawman Limited | Patent maintained as amended |
| EP07820560A | Jun, 2016 | Generics [UK] Limited | Patent maintained as amended |
| EP12703670A | Mar, 2016 | Generics [UK] Limited | Opposition rejected |
| EP12703670A | Mar, 2016 | I P S Intellectual Property Services | Opposition rejected |
| EP12703670A | Mar, 2016 | Teva Pharmaceutical Industries Ltd | Opposition rejected |
| EP09722278A | Feb, 2016 | Generics [UK] Limited (trading as Mylan) | Granted and Under Opposition |
| EP10174983A | Feb, 2016 | STADA Arzneimittel AG | Revoked |
| EP10174983A | Feb, 2016 | Actavis PTC ehf | Revoked |
| EP10174983A | Feb, 2016 | Wittkopp, Alexander | Revoked |
| EP10174983A | Feb, 2016 | Synthon B.V. | Revoked |
| EP10174983A | Feb, 2016 | Intas Pharmaceuticals Ltd. | Revoked |
| EP10174983A | Feb, 2016 | Generics [UK] Limited | Revoked |
| EP10174983A | Feb, 2016 | Ethypharm | Revoked |
| EP10174983A | Feb, 2016 | Teva Pharmaceutical Industries Ltd | Revoked |
| EP09722278A | Feb, 2016 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Granted and Under Opposition |
| EP09722278A | Feb, 2016 | Pohlman, Sandra M. | Granted and Under Opposition |
| EP10008929A | Oct, 2015 | Quark Pharmaceuticals, Inc. | Patent maintained as amended |
| EP10175197A | Jan, 2015 | Maiwald Patentanwalts GmbH | Revoked |
| EP10175197A | Jan, 2015 | Ethypharm | Revoked |
| EP10175197A | Jan, 2015 | Generics [UK] Limited (trading as Mylan) | Revoked |
| EP10175197A | Jan, 2015 | Synthon B.V./Genthon B.V. | Revoked |
| EP10175197A | Jan, 2015 | Teva Pharmaceutical Industries Ltd. | Revoked |
| EP06827689A | Oct, 2014 | Maiwald Patentanwalts GmbH | Revoked |
| EP01935167A | Jan, 2014 | Taylor Wessing LLP | Revoked |
| EP01935167A | Jan, 2014 | BIOGARAN | Revoked |
| EP01935167A | Jan, 2014 | Accord Healthcare Ltd | Revoked |
| EP01935167A | Jan, 2014 | Synthon B.V. | Revoked |
| EP01935167A | Jan, 2014 | Sanovel IIaç San. ve Tic. A.S. | Revoked |
| EP01935167A | Dec, 2013 | Genericon Pharma Gesellschaft m.b.H. | Revoked |
| EP01935167A | Nov, 2013 | STADA Arzneimittel AG | Revoked |
| EP01935167A | Sep, 2013 | PFIZER LIMITED | Revoked |
| EP01935167A | Sep, 2013 | Hikma Pharma GmbH | Revoked |
| EP01935167A | Aug, 2013 | Fresenius Kabi Deutschland GmbH | Revoked |
| EP10008931A | Jul, 2013 | Alnylam Pharmaceuticals Inc. | Opposition procedure closed |
| EP03716126A | Jul, 2013 | Alnylam Pharmaceuticals Inc. | Opposition procedure closed |
| EP01935167A | Jun, 2013 | medac Gesellschaft für klinische Spezialpräparate mbH | Revoked |
| EP01935167A | Jun, 2013 | Dr. Reddy's Laboratories Ltd. / Betapharm Arznei- mittel GmbH | Revoked |
| EP10008930A | May, 2013 | Quark Pharmaceuticals, Inc. | Patent maintained as amended |
| EP10008930A | May, 2013 | Alnylam Pharmaceuticals Inc. | Patent maintained as amended |
| EP01935167A | May, 2013 | CHEMI SPA | Revoked |
| EP01935167A | May, 2013 | Actavis Group Ptc Ehf | Revoked |
| EP01935167A | May, 2013 | hameln rds gmbh | Revoked |
| EP01935167A | Apr, 2013 | Teva Pharmaceutical Industries LTD. | Revoked |
| EP01935167A | Apr, 2013 | Generics [UK] Limited | Revoked |
| EP06800109A | Mar, 2013 | Actavis Group Ptc Ehf | Revoked |
| EP06800109A | Mar, 2013 | D YOUNG & CO | Revoked |
| EP04768542A | Aug, 2012 | Teva UK Limited | Revoked |
| EP03743684A | Jun, 2011 | Alcon Research, Ltd. | Patent maintained as amended |
| EP03743684A | May, 2011 | Dharmacon, Inc. | Patent maintained as amended |
| EP03743684A | May, 2011 | Alnylam Pharmaceuticals Inc. | Patent maintained as amended |
| EP03743684A | May, 2011 | Novartis AG | Patent maintained as amended |
| EP03743684A | May, 2011 | Sanofi-Aventis Deutschland GmbH | Patent maintained as amended |
| EP02702247A | Dec, 2010 | Sirna Therapeutics | Revoked |
| EP02702247A | Dec, 2010 | Silence Therapeutics AG | Revoked |
| EP03732397A | Jan, 2010 | Sanovel Ilac Sanayii ve Ticaret A.S. | Revoked |
| EP03732397A | Jan, 2010 | KRKA, d.d., Novo mesto | Revoked |
| EP03732397A | Jan, 2010 | Teva Pharmaceutical Industries Ltd. | Revoked |
| EP03732397A | Jan, 2010 | Lupin Limited | Revoked |
| EP05002454A | Sep, 2009 | Silence Therapeutics AG | Granted and Under Opposition |
| EP05002454A | Sep, 2009 | ROQUES, Sarah Elizabeth | Granted and Under Opposition |
| EP05002454A | Sep, 2009 | PFIZER LIMITED | Granted and Under Opposition |
| EP05002454A | Sep, 2009 | Sanofi-Aventis Deutschland GmbH | Granted and Under Opposition |
| EP05002454A | Sep, 2009 | Sirna Therapeutics | Granted and Under Opposition |
| EP03704413A | May, 2008 | Mundipharma GmbH | Opposition procedure closed |
| EP02710786A | Feb, 2007 | Sirna Therapeutics | Opposition rejected |
| EP02003683A | Mar, 2006 | Abbott Laboratories | Patent maintained as amended |
| EP02003683A | Mar, 2006 | atugen AG | Patent maintained as amended |
| EP02003683A | Mar, 2006 | Quark Biotech, Inc. | Patent maintained as amended |
| EP02003683A | Mar, 2006 | Sirna Therapeutics, Inc. | Patent maintained as amended |
| EP00910510A | May, 2003 | AstraZeneca AB | Revoked |
| EP00910510A | May, 2003 | Novartis AG | Revoked |
| EP00910510A | May, 2003 | Isis Pharmaceuticals, Inc. | Revoked |
| EP00910510A | May, 2003 | atugen AG | Revoked |
| EP00910510A | May, 2003 | Aventis Pharma Deutschland GmbH | Revoked |
| EP00910510A | May, 2003 | Grund, Martin, Dr. | Revoked |
| EP00910510A | May, 2003 | JANSSEN PHARMACEUTICA N.V. | Revoked |
| EP00910510A | May, 2003 | Sirna Therapeutics, Inc. | Revoked |
Novartis's Family Patents
Novartis drugs have patent protection in a total of 75 countries. It's US patent count contributes only to 29.7% of its total global patent coverage. 13 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Novartis Drug List
Given below is the complete list of Novartis's drugs and the patents protecting them.
1. Afinitor
Afinitor is protected by 14 patents, out of which 11 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9006224 | Neuroendocrine tumor treatment |
01 Jul, 2028
(2 years from now)
| Active |
| US8410131
(Pediatric)
| Cancer treatment |
01 May, 2026
(9 months from now)
| Active |
| US8410131 | Cancer treatment |
01 Nov, 2025
(3 months from now)
| Active |
| US8436010
(Pediatric)
| Treatment of solid tumors with rapamycin derivatives |
22 Aug, 2022
(2 years ago)
| Expired |
| US8778962
(Pediatric)
| Treatment of solid tumors with rapamycin derivatives |
18 Aug, 2022
(2 years ago)
| Expired |
| US8436010 | Treatment of solid tumors with rapamycin derivatives |
22 Feb, 2022
(3 years ago)
| Expired |
| US8778962 | Treatment of solid tumors with rapamycin derivatives |
18 Feb, 2022
(3 years ago)
| Expired |
| US7297703
(Pediatric)
| Macrolides |
06 Jun, 2020
(5 years ago)
| Expired |
| US5665772
(Pediatric)
| O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants |
09 Mar, 2020
(5 years ago)
| Expired |
| US7297703 | Macrolides |
06 Dec, 2019
(5 years ago)
| Expired |
| US7741338 | Macrolides |
06 Dec, 2019
(5 years ago)
| Expired |
| US5665772 | O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants |
09 Sep, 2019
(5 years ago)
| Expired |
| US6004973
(Pediatric)
| Pharmaceutical compositions comprising rafamycin coprecipitates |
12 Jan, 2017
(8 years ago)
| Expired |
| US6004973 | Pharmaceutical compositions comprising rafamycin coprecipitates |
12 Jul, 2016
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Afinitor's drug page
2. Alomide
Alomide is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5457126 | Use of lodoxamide to treat ophthalmic allergic conditions |
10 Oct, 2012
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Alomide's drug page
3. Amturnide
Amturnide is protected by 3 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8183295 | Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic |
16 May, 2023
(2 years ago)
| Expired |
| US8618174 | Synergistic combinations comprising a renin inhibitor for cardiovascular diseases |
15 Nov, 2021
(3 years ago)
| Expired |
| US5559111 | δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amides |
21 Jul, 2018
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Amturnide's drug page
4. Arcapta Neohaler
Arcapta Neohaler is protected by 5 patents, out of which 4 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8479730 | Inhaler device |
11 Oct, 2028
(3 years from now)
| Active |
| US6878721 | Beta2-adrenoceptor agonists |
25 Feb, 2025
(4 months ago)
| Expired |
| US8067437 | Beta-2-adrenoreceptor agonists |
02 Jun, 2020
(5 years ago)
| Expired |
| US8658673 | BETA2-adrenoreceptor agonists |
02 Jun, 2020
(5 years ago)
| Expired |
| US8796307 | Beta2-adrenoreceptor agonists |
02 Jun, 2020
(5 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Arcapta Neohaler's drug page
5. Coartem
Coartem is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5677331 | Antimalarial compositions |
14 Oct, 2014
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Coartem's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List
6. Diovan
Diovan is protected by 5 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6294197
(Pediatric)
| Solid oral dosage forms of valsartan |
18 Dec, 2017
(7 years ago)
| Expired |
| US6294197 | Solid oral dosage forms of valsartan |
18 Jun, 2017
(8 years ago)
| Expired |
| US5972990
(Pediatric)
| Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims |
26 Apr, 2017
(8 years ago)
| Expired |
| US5972990 | Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims |
26 Oct, 2016
(8 years ago)
| Expired |
| US5399578
(Pediatric)
| Acyl compounds |
21 Sep, 2012
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Diovan's drug page
7. Diovan Hct
Diovan Hct is protected by 3 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6294197
(Pediatric)
| Solid oral dosage forms of valsartan |
18 Dec, 2017
(7 years ago)
| Expired |
| US6294197 | Solid oral dosage forms of valsartan |
18 Jun, 2017
(8 years ago)
| Expired |
| US5399578
(Pediatric)
| Acyl compounds |
21 Sep, 2012
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Diovan Hct's drug page
8. Emadine
Emadine is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5441958 | Ophthalmic compositions comprising emedastine and methods for their use |
08 Dec, 2013
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Emadine's drug page
9. Entresto Sprinkle
Entresto Sprinkle is protected by 4 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10722471 | Galenic formulations of organic compounds |
02 Feb, 2037
(11 years from now)
| Active |
| US8877938 | Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations |
27 May, 2027
(1 year, 10 months from now)
| Active |
| US9388134 | Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl)-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations |
08 Nov, 2026
(1 year, 4 months from now)
| Active |
| US8101659 | Methods of treatment and pharmaceutical composition |
15 Jan, 2025
(5 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Entresto Sprinkle's drug page
10. Exelon
Exelon is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5602176 | Phenyl carbamate |
11 Feb, 2014
(11 years ago)
| Expired |
| US4948807 | Phenyl carbamates |
14 Aug, 2012
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Exelon's drug page
11. Exforge
Exforge is protected by 4 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6395728 | Method of treatment and pharmaceutical composition |
08 Jul, 2019
(5 years ago)
| Expired |
| US6294197
(Pediatric)
| Solid oral dosage forms of valsartan |
18 Dec, 2017
(7 years ago)
| Expired |
| US6294197 | Solid oral dosage forms of valsartan |
18 Jun, 2017
(8 years ago)
| Expired |
| US5399578
(Pediatric)
| Acyl compounds |
21 Sep, 2012
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Exforge's drug page
12. Exforge Hct
Exforge Hct is protected by 6 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8475839
(Pediatric)
| Solid dosage forms of valsartan, amlodipine and hydrochlorothiazide and method of making the same |
16 Nov, 2023
(1 year, 7 months ago)
| Expired |
| US8101599 | Pharmaceutical composition containing anti-hypertensive agents |
16 May, 2023
(2 years ago)
| Expired |
| US8475839 | Solid dosage forms of valsartan, amlodipine and hydrochlorothiazide and method of making the same |
16 May, 2023
(2 years ago)
| Expired |
| US6294197
(Pediatric)
| Solid oral dosage forms of valsartan |
18 Dec, 2017
(7 years ago)
| Expired |
| US6294197 | Solid oral dosage forms of valsartan |
18 Jun, 2017
(8 years ago)
| Expired |
| US5399578
(Pediatric)
| Acyl compounds |
21 Sep, 2012
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Exforge Hct's drug page
13. Exjade
Exjade is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6465504 | Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators |
05 Apr, 2019
(6 years ago)
| Expired |
| US6596750 | Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators |
24 Jun, 2017
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Exjade's drug page
14. Fabhalta
Fabhalta is protected by 6 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11951101 | Methods of using factor B inhibitors |
15 Jul, 2041
(16 years from now)
| Active |
| US11603363 | Crystalline form of LNP023 |
25 May, 2041
(15 years from now)
| Active |
| US11723901 | Uses of piperidinyl-indole derivatives |
30 Aug, 2038
(13 years from now)
| Active |
| US12285422 | Uses of piperidinyl-indole derivatives |
30 Aug, 2038
(13 years from now)
| Active |
| US10093663 | Piperidinyl-indole derivatives complement factor B inhibitors and uses thereof |
14 Jul, 2034
(9 years from now)
| Active |
| US9682968 | Piperidinyl-indole derivatives complement factor B inhibitors and uses thereof |
14 Jul, 2034
(9 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Fabhalta's drug page
15. Famvir
Famvir is protected by 8 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5840763
(Pediatric)
| Treatment of a latent infection of herpes viruses |
01 Mar, 2016
(9 years ago)
| Expired |
| US5916893
(Pediatric)
| Treatment of a latent infection of herpes virus |
01 Mar, 2016
(9 years ago)
| Expired |
| US5840763 | Treatment of a latent infection of herpes viruses |
01 Sep, 2015
(9 years ago)
| Expired |
| US5916893 | Treatment of a latent infection of herpes virus |
01 Sep, 2015
(9 years ago)
| Expired |
| US5866581
(Pediatric)
| Penciclovir for the treatment of post therapeutic neuralgia |
04 Apr, 2015
(10 years ago)
| Expired |
| US6124304
(Pediatric)
| Penciclovir for the treatment of zoster associated pain |
04 Apr, 2015
(10 years ago)
| Expired |
| US5866581 | Penciclovir for the treatment of post therapeutic neuralgia |
04 Oct, 2014
(10 years ago)
| Expired |
| US6124304 | Penciclovir for the treatment of zoster associated pain |
04 Oct, 2014
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Famvir's drug page
16. Foradil
Foradil is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6887459 | Aerosol composition comprising formoterol |
28 Nov, 2020
(4 years ago)
| Expired |
| US6488027 | Powder inhaler |
08 Mar, 2019
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Foradil's drug page
17. Gilenya
Gilenya is protected by 11 patents, out of which 4 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9592208
(Pediatric)
| Formulations comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol |
30 Sep, 2032
(7 years from now)
| Active |
| US9592208 | Formulations comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol |
30 Mar, 2032
(6 years from now)
| Active |
| US10543179 | Dosage regimen of an S1P receptor modulator |
25 Dec, 2027
(2 years from now)
| Active |
| US9187405
(Pediatric)
| S1P receptor modulators for treating relasping-remitting multiple sclerosis |
25 Dec, 2027
(2 years from now)
| Active |
| US9187405 | S1P receptor modulators for treating relasping-remitting multiple sclerosis |
25 Jun, 2027
(1 year, 11 months from now)
| Active |
| US8324283
(Pediatric)
| Solid pharmaceutical compositions comprising a SIP receptor agonist and a sugar alcohol |
29 Sep, 2026
(1 year, 2 months from now)
| Active |
| US8324283 | Solid pharmaceutical compositions comprising a SIP receptor agonist and a sugar alcohol |
29 Mar, 2026
(8 months from now)
| Active |
| US5604229
(Pediatric)
| 2-amino-1,3-propanediol compound and immunosuppressant |
18 Aug, 2019
(5 years ago)
| Expired |
| US5604229 | 2-amino-1,3-propanediol compound and immunosuppressant |
18 Feb, 2019
(6 years ago)
| Expired |
| US6004565 | Compositions and methods of using compositions with accelerated lymphocyte homing immunosuppressive properties |
23 Sep, 2017
(7 years ago)
| Expired |
| US5604229 | 2-amino-1,3-propanediol compound and immunosuppressant |
18 Feb, 2014
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Gilenya's drug page
18. Gleevec
Gleevec is protected by 12 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6958335
(Pediatric)
| Treatment of gastrointestinal stromal tumors |
19 Jun, 2022
(3 years ago)
| Expired |
| US6958335 | Treatment of gastrointestinal stromal tumors |
19 Dec, 2021
(3 years ago)
| Expired |
| US6894051
(Pediatric)
| Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use |
23 Nov, 2019
(5 years ago)
| Expired |
| US7544799
(Pediatric)
| Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use |
16 Jul, 2019
(5 years ago)
| Expired |
| USRE43932
(Pediatric)
| Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use |
16 Jul, 2019
(5 years ago)
| Expired |
| US6894051 | Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use |
23 May, 2019
(6 years ago)
| Expired |
| US7544799 | Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use |
16 Jan, 2019
(6 years ago)
| Expired |
| USRE43932 | Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use |
16 Jan, 2019
(6 years ago)
| Expired |
| USRE43932
(Pediatric)
| Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use |
16 Jan, 2019
(6 years ago)
| Expired |
| USRE43932 | Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use |
16 Jul, 2018
(6 years ago)
| Expired |
| US5521184
(Pediatric)
| Pyrimidine derivatives and processes for the preparation thereof |
04 Jul, 2015
(10 years ago)
| Expired |
| US5521184 | Pyrimidine derivatives and processes for the preparation thereof |
04 Jan, 2015
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Gleevec's drug page
19. Izba
Izba is protected by 4 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8178582 | Pharmaceutical compositions having desirable bioavailability |
10 Oct, 2029
(4 years from now)
| Active |
| US8722735 | Pharmaceutical compositions having desirable bioavailability |
10 Oct, 2029
(4 years from now)
| Active |
| US8754123 | Pharmaceutical compositions having desirable bioavailability |
19 May, 2029
(3 years from now)
| Active |
| US9144561 | Pharmaceutical compositions having desirable bioavailability |
13 Mar, 2029
(3 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Izba's drug page
20. Jadenu Sprinkle
Jadenu Sprinkle is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6465504 | Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators |
05 Apr, 2019
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Jadenu Sprinkle's drug page
21. Kisqali
Kisqali is protected by 9 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10799506 | Ribociclib tablet |
14 Apr, 2036
(10 years from now)
| Active |
| US12064434 | Ribociclib tablet |
14 Apr, 2036
(10 years from now)
| Active |
| US9193732 | Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-D]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof |
09 Nov, 2031
(6 years from now)
| Active |
| US9868739 | Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof |
09 Nov, 2031
(6 years from now)
| Active |
| US8415355 | Pyrrolopyrimidine compounds and their uses |
13 Mar, 2031
(5 years from now)
| Active |
| US8685980 | Pyrrolopyrimidine compounds and their uses |
25 May, 2030
(4 years from now)
| Active |
| US8962630 | Pyrrolopyrimidine compounds and their uses |
09 Dec, 2029
(4 years from now)
| Active |
| US9416136 | Pyrrolopyrimidine compounds and their uses |
20 Aug, 2029
(4 years from now)
| Active |
| US8324225 | Pyrrolopyrimidine compounds and their uses |
17 Jun, 2028
(2 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Kisqali's drug page
22. Kisqali Femara Co-pack (copackaged)
Kisqali Femara Co-pack (copackaged) is protected by 9 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10799506 | Ribociclib tablet |
14 Apr, 2036
(10 years from now)
| Active |
| US12064434 | Ribociclib tablet |
14 Apr, 2036
(10 years from now)
| Active |
| US9193732 | Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-D]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof |
09 Nov, 2031
(6 years from now)
| Active |
| US9868739 | Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof |
09 Nov, 2031
(6 years from now)
| Active |
| US8415355 | Pyrrolopyrimidine compounds and their uses |
13 Mar, 2031
(5 years from now)
| Active |
| US8685980 | Pyrrolopyrimidine compounds and their uses |
25 May, 2030
(4 years from now)
| Active |
| US8962630 | Pyrrolopyrimidine compounds and their uses |
09 Dec, 2029
(4 years from now)
| Active |
| US9416136 | Pyrrolopyrimidine compounds and their uses |
20 Aug, 2029
(4 years from now)
| Active |
| US8324225 | Pyrrolopyrimidine compounds and their uses |
17 Jun, 2028
(2 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Kisqali Femara Co-pack (copackaged)'s drug page
23. Leqvio
Leqvio is protected by 20 patents, out of which 11 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10851377 | Methods and compositions for treating a proprotein convertase subtilisin kexin (PCSK9) gene-associated disorder |
25 Aug, 2036
(11 years from now)
| Active |
| US10125369 | PCSK9 iRNA compositions and methods of use thereof |
18 Aug, 2034
(9 years from now)
| Active |
| US8106022 | Carbohydrate conjugates as delivery agents for oligonucleotides |
12 Dec, 2029
(4 years from now)
| Active |
| US10806791 | Carbohydrate conjugates as delivery agents for oligonucleotides |
04 Dec, 2028
(3 years from now)
| Active |
| US8828956 | Carbohydrate conjugates as delivery agents for oligonucleotides |
04 Dec, 2028
(3 years from now)
| Active |
| US9370582 | Carbohydrate conjugates as delivery agents for oligonucleotides |
04 Dec, 2028
(3 years from now)
| Active |
| US10131907 | Glycoconjugates of RNA interference agents |
24 Aug, 2028
(3 years from now)
| Active |
| US8222222 | Compositions and methods for inhibiting expression of the PCSK9 gene |
29 Dec, 2027
(2 years from now)
| Active |
| US8809292 | Compositions and methods for inhibiting expression of the PCSK9 gene |
10 May, 2027
(1 year, 10 months from now)
| Active |
| US11530408 | Therapeutic compositions |
18 May, 2024
(1 year, 1 month ago)
| Expired |
| US10273477 | Therapeutic compositions |
08 Mar, 2024
(1 year, 3 months ago)
| Expired |
| US10669544 | Therapeutic compositions |
08 Mar, 2024
(1 year, 3 months ago)
| Expired |
| US9708615 | Therapeutic compositions |
08 Mar, 2024
(1 year, 3 months ago)
| Expired |
| US9708610 | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
01 Jan, 2024
(1 year, 6 months ago)
| Expired |
| US10266825 | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
04 Nov, 2023
(1 year, 7 months ago)
| Expired |
| US11078485 | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
04 Nov, 2023
(1 year, 7 months ago)
| Expired |
| US8232383 | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
20 Feb, 2023
(2 years ago)
| Expired |
| US10590418 | Methods and compositions for RNAi mediated inhibition of gene expression in mammals |
19 Jul, 2022
(2 years ago)
| Expired |
| US8546143 | Compositions and methods for inhibiting expression of a target gene |
23 Apr, 2022
(3 years ago)
| Expired |
| US9074213 | Compositions and methods for inhibiting expression of a target gene |
09 Mar, 2022
(3 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Leqvio's drug page
24. Locametz
Locametz is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12109277 | Apparatus and method for penetrating and enlarging adjacent tissue layers |
09 Mar, 2036
(10 years from now)
| Active |
| US11369590 | PSMA binding ligand-linker conjugates and methods for using |
15 Aug, 2028
(3 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Locametz's drug page
25. Mayzent
Mayzent is protected by 4 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11944602 | Treatment of autoimmune disease in a patient receiving additionally a beta-blocker |
23 Apr, 2036
(10 years from now)
| Active |
| US12071402 | Immunosuppressant formulations |
05 Jan, 2032
(6 years from now)
| Active |
| US8492441 | Dosage regimen of an S1P receptor agonist |
30 Nov, 2030
(5 years from now)
| Active |
| US7939519 | Immunosuppresant compounds and compositions |
27 Aug, 2028
(3 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Mayzent's drug page
26. Mekinist
Mekinist is protected by 18 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10869869
(Pediatric)
| Method of adjuvant cancer treatment |
28 Feb, 2034
(8 years from now)
| Active |
| US10869869 | Method of adjuvant cancer treatment |
30 Aug, 2033
(8 years from now)
| Active |
| US8580304
(Pediatric)
| Pharmaceutical composition |
28 Jul, 2032
(7 years from now)
| Active |
| US9155706
(Pediatric)
| Pharmaceutical composition |
28 Jul, 2032
(7 years from now)
| Active |
| US9271941
(Pediatric)
| Pharmaceutical composition |
28 Jul, 2032
(7 years from now)
| Active |
| US9399021
(Pediatric)
| Pharmaceutical composition |
28 Jul, 2032
(7 years from now)
| Active |
| US8580304 | Pharmaceutical composition |
28 Jan, 2032
(6 years from now)
| Active |
| US9155706 | Pharmaceutical composition |
28 Jan, 2032
(6 years from now)
| Active |
| US9271941 | Pharmaceutical composition |
28 Jan, 2032
(6 years from now)
| Active |
| US9399021 | Pharmaceutical composition |
28 Jan, 2032
(6 years from now)
| Active |
| US8703781
(Pediatric)
| Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors |
15 Apr, 2031
(5 years from now)
| Active |
| US8952018
(Pediatric)
| Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors |
15 Apr, 2031
(5 years from now)
| Active |
| US8703781 | Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors |
15 Oct, 2030
(5 years from now)
| Active |
| US8952018 | Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors |
15 Oct, 2030
(5 years from now)
| Active |
| US7378423
(Pediatric)
| Pyrimidine compound and medical use thereof |
29 Nov, 2027
(2 years from now)
| Active |
| US7378423 | Pyrimidine compound and medical use thereof |
29 May, 2027
(1 year, 10 months from now)
| Active |
| US8835443
(Pediatric)
| Pyrimidine compound and medical use thereof |
10 Dec, 2025
(5 months from now)
| Active |
| US8835443 | Pyrimidine compound and medical use thereof |
10 Jun, 2025
(22 days ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Mekinist's drug page
27. Myfortic
Myfortic is protected by 3 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6306900 | Enteric coated pharmaceutical compositions |
27 Feb, 2018
(7 years ago)
| Expired |
| US6025391 | Enteric-coated pharmaceutical compositions of mycophenolate |
10 Apr, 2017
(8 years ago)
| Expired |
| US6172107 | Entric-coated pharmaceutical compositions |
10 Apr, 2017
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Myfortic's drug page
28. Neoral
Neoral is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5985321 | Soft gelatin capsule manufacture |
26 Sep, 2014
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Neoral's drug page
29. Patanase
Patanase is protected by 4 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7977376
(Pediatric)
| Olopatadine formulations for topical nasal administration |
02 Aug, 2023
(1 year, 10 months ago)
| Expired |
| US8399508
(Pediatric)
| Olopatadine formulations for topical nasal administration |
17 Mar, 2023
(2 years ago)
| Expired |
| US7977376 | Olopatadine formulations for topical nasal administration |
02 Feb, 2023
(2 years ago)
| Expired |
| US8399508 | Olopatadine formulations for topical nasal administration |
17 Sep, 2022
(2 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Patanase's drug page
30. Piqray
Piqray is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8227462 | Pyrrolidine-1,2-dicarboxamide derivatives |
29 Apr, 2033
(7 years from now)
| Active |
| US8476268 | Pyrrolidine-1,2-dicarboxamide derivatives |
10 Sep, 2029
(4 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Piqray's drug page
31. Pluvicto
Pluvicto is protected by 5 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12208102 | Methods of treating cancer |
18 Sep, 2041
(16 years from now)
| Active |
| US11951190 | Use of labeled inhibitors of prostate specific membrane antigen (PSMA), as agents for the treatment of prostate cancer |
12 Nov, 2035
(10 years from now)
| Active |
| US10398791 | Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
17 Oct, 2034
(9 years from now)
| Active |
| US10406240 | PSMA binding ligand-linker conjugates and methods for using |
15 Aug, 2028
(3 years from now)
| Active |
| US11318121 | PSMA binding ligand-linker conjugates and methods for using |
15 Aug, 2028
(3 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Pluvicto's drug page
32. Promacta
Promacta is protected by 28 patents, out of which 14 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8052993
(Pediatric)
| 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
01 Feb, 2028
(2 years from now)
| Active |
| US8052994
(Pediatric)
| 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
01 Feb, 2028
(2 years from now)
| Active |
| US8052995
(Pediatric)
| 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
01 Feb, 2028
(2 years from now)
| Active |
| US8062665
(Pediatric)
| 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1 ,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
01 Feb, 2028
(2 years from now)
| Active |
| US8071129
(Pediatric)
| 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
01 Feb, 2028
(2 years from now)
| Active |
| US8828430
(Pediatric)
| 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
01 Feb, 2028
(2 years from now)
| Active |
| US8052993 | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
01 Aug, 2027
(2 years from now)
| Active |
| US8052994 | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
01 Aug, 2027
(2 years from now)
| Active |
| US8052995 | 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
01 Aug, 2027
(2 years from now)
| Active |
| US8062665 | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1 ,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
01 Aug, 2027
(2 years from now)
| Active |
| US8071129 | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
01 Aug, 2027
(2 years from now)
| Active |
| US8828430 | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
01 Aug, 2027
(2 years from now)
| Active |
| US7547719
(Pediatric)
| 3′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine) |
13 Jan, 2026
(6 months from now)
| Active |
| US7547719 | 3′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine) |
13 Jul, 2025
(10 days from now)
| Active |
| US7795293
(Pediatric)
| 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
21 Nov, 2023
(1 year, 7 months ago)
| Expired |
| US7795293 | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
21 May, 2023
(2 years ago)
| Expired |
| US7160870
(Pediatric)
| Thrombopoietin mimetics |
20 May, 2023
(2 years ago)
| Expired |
| US7160870 | Thrombopoietin mimetics |
20 Nov, 2022
(2 years ago)
| Expired |
| US7332481
(Pediatric)
| Thrombopoietin mimetics |
24 Nov, 2021
(3 years ago)
| Expired |
| US7452874
(Pediatric)
| Thrombopoietin mimetics |
24 Nov, 2021
(3 years ago)
| Expired |
| US7473686
(Pediatric)
| Thrombopoietin mimetics |
24 Nov, 2021
(3 years ago)
| Expired |
| US7790704
(Pediatric)
| Thrombopoietin mimetics |
24 Nov, 2021
(3 years ago)
| Expired |
| US7332481 | Thrombopoietin mimetics |
24 May, 2021
(4 years ago)
| Expired |
| US7452874 | Thrombopoietin mimetics |
24 May, 2021
(4 years ago)
| Expired |
| US7473686 | Thrombopoietin mimetics |
24 May, 2021
(4 years ago)
| Expired |
| US7790704 | Thrombopoietin mimetics |
24 May, 2021
(4 years ago)
| Expired |
| US6280959
(Pediatric)
| Metal complexes |
30 Apr, 2019
(6 years ago)
| Expired |
| US6280959 | Metal complexes |
30 Oct, 2018
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Promacta's drug page
33. Promacta Kit
Promacta Kit is protected by 16 patents, out of which 14 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7547719
(Pediatric)
| 3′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine) |
13 Jan, 2026
(6 months from now)
| Active |
| US7547719 | 3′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine) |
13 Jul, 2025
(10 days from now)
| Active |
| US7795293
(Pediatric)
| 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
21 Nov, 2023
(1 year, 7 months ago)
| Expired |
| US7795293 | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
21 May, 2023
(2 years ago)
| Expired |
| US7160870
(Pediatric)
| Thrombopoietin mimetics |
20 May, 2023
(2 years ago)
| Expired |
| US7160870 | Thrombopoietin mimetics |
20 Nov, 2022
(2 years ago)
| Expired |
| US7332481
(Pediatric)
| Thrombopoietin mimetics |
24 Nov, 2021
(3 years ago)
| Expired |
| US7452874
(Pediatric)
| Thrombopoietin mimetics |
24 Nov, 2021
(3 years ago)
| Expired |
| US7473686
(Pediatric)
| Thrombopoietin mimetics |
24 Nov, 2021
(3 years ago)
| Expired |
| US7790704
(Pediatric)
| Thrombopoietin mimetics |
24 Nov, 2021
(3 years ago)
| Expired |
| US7332481 | Thrombopoietin mimetics |
24 May, 2021
(4 years ago)
| Expired |
| US7452874 | Thrombopoietin mimetics |
24 May, 2021
(4 years ago)
| Expired |
| US7473686 | Thrombopoietin mimetics |
24 May, 2021
(4 years ago)
| Expired |
| US7790704 | Thrombopoietin mimetics |
24 May, 2021
(4 years ago)
| Expired |
| US6280959
(Pediatric)
| Metal complexes |
30 Apr, 2019
(6 years ago)
| Expired |
| US6280959 | Metal complexes |
30 Oct, 2018
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Promacta Kit's drug page
34. Rydapt
Rydapt is protected by 3 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8575146 | Pharmaceutical uses of staurosporine derivatives |
02 Dec, 2030
(5 years from now)
| Active |
| US7973031 | Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity |
09 Oct, 2028
(3 years from now)
| Active |
| US8222244 | Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity |
29 Oct, 2022
(2 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Rydapt's drug page
35. Sandostatin
Sandostatin is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5753618
(Pediatric)
| Somatostatin analogue composition and use in treating breast cancer |
19 Nov, 2015
(9 years ago)
| Expired |
| US5753618 | Somatostatin analogue composition and use in treating breast cancer |
19 May, 2015
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Sandostatin's drug page
36. Sandostatin Lar
Sandostatin Lar is protected by 10 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5922338
(Pediatric)
| Polyol esters, their preparation and use in depot forms of pharmacologically active agents |
13 Jan, 2017
(8 years ago)
| Expired |
| US5922682
(Pediatric)
| Polyol esters, their preparation and use in depot forms of pharmacologically active agents |
13 Jan, 2017
(8 years ago)
| Expired |
| US5922338 | Polyol esters, their preparation and use in depot forms of pharmacologically active agents |
13 Jul, 2016
(8 years ago)
| Expired |
| US5922682 | Polyol esters, their preparation and use in depot forms of pharmacologically active agents |
13 Jul, 2016
(8 years ago)
| Expired |
| US5688530
(Pediatric)
| Sustained release formulations of water soluble peptides |
18 May, 2015
(10 years ago)
| Expired |
| US5639480
(Pediatric)
| Sustained release formulations of water soluble peptides |
17 Dec, 2014
(10 years ago)
| Expired |
| US5688530 | Sustained release formulations of water soluble peptides |
18 Nov, 2014
(10 years ago)
| Expired |
| US5639480 | Sustained release formulations of water soluble peptides |
17 Jun, 2014
(11 years ago)
| Expired |
| US5538739
(Pediatric)
| Sustained release formulations of water soluble peptides |
23 Jan, 2014
(11 years ago)
| Expired |
| US5538739 | Sustained release formulations of water soluble peptides |
23 Jul, 2013
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Sandostatin Lar's drug page
37. Scemblix
Scemblix is protected by 4 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12252479 | Crystalline forms OF N-[4-(chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide |
17 May, 2040
(14 years from now)
| Active |
| US11407735 | Crystalline forms of N-[4-(Chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide |
14 May, 2040
(14 years from now)
| Active |
| US12252478 | Crystalline forms of N-[4-(chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide |
14 May, 2040
(14 years from now)
| Active |
| US8829195 | Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 |
13 May, 2033
(7 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Scemblix's drug page
38. Seebri Neohaler
Seebri Neohaler is protected by 15 patents, out of which 13 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8182838 | Dry powder composition comprising co-jet milled particles for pulmonary inhalation |
20 Oct, 2028
(3 years from now)
| Active |
| US8479730 | Inhaler device |
11 Oct, 2028
(3 years from now)
| Active |
| US7736670 | Method of making particles for use in a pharmaceutical composition |
27 Jun, 2021
(4 years ago)
| Expired |
| US8048451 | Pharmaceutical compositions for inhalation |
27 Jun, 2021
(4 years ago)
| Expired |
| US8303991 | Method of making particles for use in a pharmaceutical composition |
27 Jun, 2021
(4 years ago)
| Expired |
| US8435567 | Pharmaceutical compositions of hydrophobic surface-modified active substance microparticles for inhalation |
27 Jun, 2021
(4 years ago)
| Expired |
| US8580306 | Particles for use in a pharmaceutical composition |
27 Jun, 2021
(4 years ago)
| Expired |
| US8956661 | Method of making composite particles for use in pharmaceutical compositions and composite particles and compositions thereof |
27 Jun, 2021
(4 years ago)
| Expired |
| US9931304 | Method of making particles for use in a pharmaceutical composition |
27 Jun, 2021
(4 years ago)
| Expired |
| US9962338 | Method of making particles for use in a pharmaceutical composition |
27 Jun, 2021
(4 years ago)
| Expired |
| US7229607 | Treatment of respiratory disease |
09 Apr, 2021
(4 years ago)
| Expired |
| US8029768 | Treatment of respiratory diseases |
09 Apr, 2021
(4 years ago)
| Expired |
| US6528678 | Phosgene-free process for preparing carbamates |
24 Apr, 2018
(7 years ago)
| Expired |
| US6582678 | Carrier particles for use in dry powder inhalers |
24 Apr, 2018
(7 years ago)
| Expired |
| US6521260 | Carrier particles for use in dry powder inhalers |
31 Jan, 2016
(9 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Seebri Neohaler's drug page
39. Starlix
Starlix is protected by 6 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6559188 | Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes |
15 Sep, 2020
(4 years ago)
| Expired |
| US6878749 | Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes |
15 Sep, 2020
(4 years ago)
| Expired |
| US6641841 | Tablet composition |
14 Nov, 2017
(7 years ago)
| Expired |
| US6844008 | Tablet composition |
14 Nov, 2017
(7 years ago)
| Expired |
| US5488150 | Crystals of N-(trans-4-isopropylcyclohexycarbonyl)-D-phenylalanine and methods for preparing them |
30 Jan, 2013
(12 years ago)
| Expired |
| US5463116 | Crystals of N- (trans-4-isopropylcyclohexlycarbonyl)-D-phenylalanine and methods for preparing them |
21 Oct, 2012
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Starlix's drug page
40. Tafinlar
Tafinlar is protected by 16 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11504333
(Pediatric)
| Pharmaceutical composition |
29 Dec, 2038
(13 years from now)
| Active |
| US11504333 | Pharmaceutical composition |
29 Jun, 2038
(12 years from now)
| Active |
| US10869869
(Pediatric)
| Method of adjuvant cancer treatment |
28 Feb, 2034
(8 years from now)
| Active |
| US10869869 | Method of adjuvant cancer treatment |
30 Aug, 2033
(8 years from now)
| Active |
| US8703781
(Pediatric)
| Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors |
15 Apr, 2031
(5 years from now)
| Active |
| US8952018
(Pediatric)
| Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors |
15 Apr, 2031
(5 years from now)
| Active |
| US8703781 | Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors |
15 Oct, 2030
(5 years from now)
| Active |
| US8952018 | Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors |
15 Oct, 2030
(5 years from now)
| Active |
| US7994185
(Pediatric)
| Benzene sulfonamide thiazole and oxazole compounds |
20 Jul, 2030
(5 years from now)
| Active |
| US8415345
(Pediatric)
| Benzene sulfonamide thiazole and oxazole compounds |
20 Jul, 2030
(5 years from now)
| Active |
| US7994185 | Benzene sulfonamide thiazole and oxazole compounds |
20 Jan, 2030
(4 years from now)
| Active |
| US8415345 | Benzene sulfonamide thiazole and oxazole compounds |
20 Jan, 2030
(4 years from now)
| Active |
| US9233956
(Pediatric)
| Benzene sulfonamide thiazole and oxazole compounds |
04 Nov, 2029
(4 years from now)
| Active |
| US9233956 | Benzene sulfonamide thiazole and oxazole compounds |
04 May, 2029
(3 years from now)
| Active |
| US8835443
(Pediatric)
| Pyrimidine compound and medical use thereof |
10 Dec, 2025
(5 months from now)
| Active |
| US8835443 | Pyrimidine compound and medical use thereof |
10 Jun, 2025
(22 days ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tafinlar's drug page
41. Tasigna
Tasigna is protected by 14 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9061029
(Pediatric)
| Method of treating proliferative disorders and other pathological conditions mediated by Bcr-Abl, c-Kit, DDR1, DDR2 or PDGF-R kinase activity |
07 Oct, 2032
(7 years from now)
| Active |
| US9061029 | Method of treating proliferative disorders and other pathological conditions mediated by Bcr-Abl, c-Kit, DDR1, DDR2 or PDGF-R kinase activity |
07 Apr, 2032
(6 years from now)
| Active |
| US8163904
(Pediatric)
| Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-Benzamide |
23 Feb, 2029
(3 years from now)
| Active |
| US8163904 | Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-Benzamide |
23 Aug, 2028
(3 years from now)
| Active |
| US8293756
(Pediatric)
| Pharmaceutical compositions comprising nilotinib hydrochloride monohydrate |
25 Mar, 2028
(2 years from now)
| Active |
| US8293756 | Pharmaceutical compositions comprising nilotinib hydrochloride monohydrate |
25 Sep, 2027
(2 years from now)
| Active |
| US8389537
(Pediatric)
| Salts of 4-methyl N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide |
18 Jan, 2027
(1 year, 6 months from now)
| Active |
| US8415363
(Pediatric)
| Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide |
18 Jan, 2027
(1 year, 6 months from now)
| Active |
| US8501760
(Pediatric)
| Pharmaceutical compositions comprising nilotinib or its salt |
18 Jan, 2027
(1 year, 6 months from now)
| Active |
| US8389537 | Salts of 4-methyl N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide |
18 Jul, 2026
(1 year, 15 days from now)
| Active |
| US8415363 | Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide |
18 Jul, 2026
(1 year, 15 days from now)
| Active |
| US8501760 | Pharmaceutical compositions comprising nilotinib or its salt |
18 Jul, 2026
(1 year, 15 days from now)
| Active |
| US7169791
(Pediatric)
| Inhibitors of tyrosine kinases |
04 Jan, 2024
(1 year, 5 months ago)
| Expired |
| US7169791 | Inhibitors of tyrosine kinases |
04 Jul, 2023
(1 year, 11 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tasigna's drug page
42. Tekamlo
Tekamlo is protected by 2 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8613949 | Galenical formulations of organic compounds |
21 Dec, 2029
(4 years from now)
| Active |
| US5559111 | δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amides |
21 Jul, 2018
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tekamlo's drug page
43. Trileptal
Trileptal is protected by 4 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8119148
(Pediatric)
| Suspension comprising oxcarbazepine |
19 Jun, 2021
(4 years ago)
| Expired |
| US8119148 | Suspension comprising oxcarbazepine |
19 Dec, 2020
(4 years ago)
| Expired |
| US7037525
(Pediatric)
| Oxacarbazepine film-coated tablets |
12 Aug, 2018
(6 years ago)
| Expired |
| US7037525 | Oxacarbazepine film-coated tablets |
12 Feb, 2018
(7 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Trileptal's drug page
44. Tykerb
Tykerb is protected by 7 patents, out of which 6 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8821927 | Pharmaceutical composition |
18 Sep, 2029
(4 years from now)
| Active |
| US7157466 | Quinazoline ditosylate salt compounds |
19 Nov, 2021
(3 years ago)
| Expired |
| US6713485 | Heterocyclic compounds |
29 Sep, 2020
(4 years ago)
| Expired |
| US6727256 | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors |
08 Jan, 2019
(6 years ago)
| Expired |
| US8513262 | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors |
08 Jan, 2019
(6 years ago)
| Expired |
| US6391874 | Fused heterocyclic compounds as protein tyrosine kinase inhibitors |
11 Jul, 2017
(7 years ago)
| Expired |
| US6828320 | Heterocyclic compounds |
11 Jul, 2017
(7 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tykerb's drug page
45. Tyzeka
Tyzeka is protected by 7 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7589079 | Crystalline and amorphous forms of beta-L-2′-deoxythymidine |
11 Sep, 2023
(1 year, 9 months ago)
| Expired |
| US7858594 | Crystalline and amorphous forms of beta-L-2′-deoxythymidine |
11 Sep, 2023
(1 year, 9 months ago)
| Expired |
| US6569837 | β-L-2′-deoxy pyrimidine nucleosides for the treatment of hepatitis B |
25 Oct, 2020
(4 years ago)
| Expired |
| US6395716 | β-L-2′-deoxy-nucleosides for the treatment of hepatitis B |
10 Aug, 2019
(5 years ago)
| Expired |
| US6444652 | β-L-2'-deoxy-nucleosides for the treatment of hepatitis B |
10 Aug, 2019
(5 years ago)
| Expired |
| US6566344 | β-L-2′-deoxy-nucleosides for the treatment of hepatitis B |
10 Aug, 2019
(5 years ago)
| Expired |
| US7795238 | β-L-2′-deoxy-nucleosides for the treatment of hepatitis B |
10 Aug, 2019
(5 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tyzeka's drug page
46. Utibron Neohaler
Utibron Neohaler is protected by 20 patents, out of which 18 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8182838 | Dry powder composition comprising co-jet milled particles for pulmonary inhalation |
20 Oct, 2028
(3 years from now)
| Active |
| US8479730 | Inhaler device |
11 Oct, 2028
(3 years from now)
| Active |
| US6878721 | Beta2-adrenoceptor agonists |
25 Feb, 2025
(4 months ago)
| Expired |
| US7736670 | Method of making particles for use in a pharmaceutical composition |
27 Jun, 2021
(4 years ago)
| Expired |
| US8048451 | Pharmaceutical compositions for inhalation |
27 Jun, 2021
(4 years ago)
| Expired |
| US8303991 | Method of making particles for use in a pharmaceutical composition |
27 Jun, 2021
(4 years ago)
| Expired |
| US8435567 | Pharmaceutical compositions of hydrophobic surface-modified active substance microparticles for inhalation |
27 Jun, 2021
(4 years ago)
| Expired |
| US8580306 | Particles for use in a pharmaceutical composition |
27 Jun, 2021
(4 years ago)
| Expired |
| US8956661 | Method of making composite particles for use in pharmaceutical compositions and composite particles and compositions thereof |
27 Jun, 2021
(4 years ago)
| Expired |
| US9931304 | Method of making particles for use in a pharmaceutical composition |
27 Jun, 2021
(4 years ago)
| Expired |
| US9962338 | Method of making particles for use in a pharmaceutical composition |
27 Jun, 2021
(4 years ago)
| Expired |
| US7229607 | Treatment of respiratory disease |
09 Apr, 2021
(4 years ago)
| Expired |
| US8029768 | Treatment of respiratory diseases |
09 Apr, 2021
(4 years ago)
| Expired |
| US7820694 | Beta-2-adrenoreceptor agonists |
02 Jun, 2020
(5 years ago)
| Expired |
| US8067437 | Beta-2-adrenoreceptor agonists |
02 Jun, 2020
(5 years ago)
| Expired |
| US8283362 | Beta-2-adrenoreceptor agonists |
02 Jun, 2020
(5 years ago)
| Expired |
| US8658673 | BETA2-adrenoreceptor agonists |
02 Jun, 2020
(5 years ago)
| Expired |
| US8796307 | Beta2-adrenoreceptor agonists |
02 Jun, 2020
(5 years ago)
| Expired |
| US6582678 | Carrier particles for use in dry powder inhalers |
24 Apr, 2018
(7 years ago)
| Expired |
| US6521260 | Carrier particles for use in dry powder inhalers |
31 Jan, 2016
(9 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Utibron Neohaler's drug page
47. Valturna
Valturna is protected by 2 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8168616 | Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension |
03 Jul, 2026
(a year from now)
| Active |
| US5559111 | δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amides |
21 Jul, 2018
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Valturna's drug page
48. Vanrafia
Vanrafia is protected by 7 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11491137 | Methods of improving renal function |
16 Dec, 2040
(15 years from now)
| Active |
| US11998526 | Methods of improving renal function |
16 Dec, 2040
(15 years from now)
| Active |
| US12121509 | Methods of improving renal function |
16 Dec, 2040
(15 years from now)
| Active |
| US10016393 | Stabilized pharmaceutical dosage forms comprising atrasentan |
07 Jul, 2034
(9 years from now)
| Active |
| US9364458 | Stabilized pharmaceutical dosage forms comprising atrasentan |
07 Jul, 2034
(9 years from now)
| Active |
| US11874283 | Method and compositions for the treatment and detection of endothelin-1 related kidney diseases |
18 Feb, 2032
(6 years from now)
| Active |
| US8623819 | Therapy for complications of diabetes |
22 Aug, 2028
(3 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vanrafia's drug page
49. Vijoice
Vijoice is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8227462 | Pyrrolidine-1,2-dicarboxamide derivatives |
29 Apr, 2033
(7 years from now)
| Active |
| US8476268 | Pyrrolidine-1,2-dicarboxamide derivatives |
10 Sep, 2029
(4 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vijoice's drug page
50. Vitravene Preservative Free
Vitravene Preservative Free is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5442049 | Oligonucleotides for modulating the effects of cytomegalovirus infections |
15 Aug, 2012
(12 years ago)
| Expired |
| US5595978 | Composition and method for treatment of CMV retinites |
15 Aug, 2012
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vitravene Preservative Free's drug page
51. Votrient
Votrient is protected by 3 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7105530 | Pyrimidineamines as angiogenesis modulators |
19 Oct, 2023
(1 year, 8 months ago)
| Expired |
| US7262203 | Pyrimidineamines as angiogenesis modulators |
19 Dec, 2021
(3 years ago)
| Expired |
| US8114885 | Chemical compounds |
19 Dec, 2021
(3 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Votrient's drug page
52. Zometa
Zometa is protected by 5 patents, out of which 3 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7932241 | Pharmaceutical products comprising bisphosphonates |
05 Feb, 2028
(2 years from now)
| Active |
| US8324189
(Pediatric)
| Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases |
29 Nov, 2025
(4 months from now)
| Active |
| US8324189 | Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases |
29 May, 2025
(a month ago)
| Expired |
| US4939130
(Pediatric)
| Substituted alkanediphosphonic acids and pharmaceutical use |
02 Mar, 2013
(12 years ago)
| Expired |
| US4939130 | Substituted alkanediphosphonic acids and pharmaceutical use |
02 Sep, 2012
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zometa's drug page
53. Zortress
Zortress is protected by 10 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5665772
(Pediatric)
| O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants |
09 Mar, 2020
(5 years ago)
| Expired |
| US5665772 | O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants |
09 Sep, 2019
(5 years ago)
| Expired |
| US6239124
(Pediatric)
| Pharmaceutical compositions for the treatment of transplant rejection or autoimmune or inflammatory conditions comprising cyclosporin A and 40-0-(2-hydroxyethyl)-rapamycin |
11 Feb, 2018
(7 years ago)
| Expired |
| US6455518
(Pediatric)
| Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-O-(2-hydroxyethyl)-rapamycin |
29 Jan, 2018
(7 years ago)
| Expired |
| US6239124 | Pharmaceutical compositions for the treatment of transplant rejection or autoimmune or inflammatory conditions comprising cyclosporin A and 40-0-(2-hydroxyethyl)-rapamycin |
11 Aug, 2017
(7 years ago)
| Expired |
| US6455518 | Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-O-(2-hydroxyethyl)-rapamycin |
29 Jul, 2017
(7 years ago)
| Expired |
| US6004973
(Pediatric)
| Pharmaceutical compositions comprising rafamycin coprecipitates |
12 Jan, 2017
(8 years ago)
| Expired |
| US6004973 | Pharmaceutical compositions comprising rafamycin coprecipitates |
12 Jul, 2016
(8 years ago)
| Expired |
| US6440990
(Pediatric)
| O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants |
24 Mar, 2014
(11 years ago)
| Expired |
| US6440990 | O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants |
24 Sep, 2013
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zortress's drug page
54. Zykadia
Zykadia is protected by 13 patents, out of which 5 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8703787 | Methods of using ALK inhibitors |
02 Feb, 2032
(6 years from now)
| Active |
| US9309229 | Crystalline forms of 5-chloro-N2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2, 4-diamine |
18 Jan, 2032
(6 years from now)
| Active |
| US8039474 | 2,3,4,9-tetrahydro-1H-carbazole derivatives as CRTH2 receptor antagonists |
29 Jun, 2030
(4 years from now)
| Active |
| US8039479 | Compounds and compositions as protein kinase inhibitors |
29 Jun, 2030
(4 years from now)
| Active |
| US7964592 | 2,4-di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders |
29 Apr, 2028
(2 years from now)
| Active |
| US8377921 | Compounds and compositions as protein kinase inhibitors |
20 Nov, 2027
(2 years from now)
| Active |
| US8399450 | Compounds and compositions as protein kinase inhibitors |
20 Nov, 2027
(2 years from now)
| Active |
| US7893074 | 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders |
25 Apr, 2026
(9 months from now)
| Active |
| US8188276 | 2,4-pyrimidinediamine compounds and their uses |
31 Jan, 2023
(2 years ago)
| Expired |
| US8835430 | 2,4-pyrimidinediamine compounds and their uses |
31 Jan, 2023
(2 years ago)
| Expired |
| US9018204 | 2,4-pyrimidinediamine compounds and their uses |
31 Jan, 2023
(2 years ago)
| Expired |
| US9416112 | 2,4-pyrimidinediamine compounds and their uses |
31 Jan, 2023
(2 years ago)
| Expired |
| US7153964 | Pyrimidine compounds |
26 Feb, 2021
(4 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zykadia's drug page